Track Amgen Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Amgen Inc. AMGN.VI · Stock Open Amgen Inc. in new tab

376.85 EUR
P/E
27.31
EPS
13.80
Yield
2.29%
P/B
20.36
ROE
91.47
Beta
0.41
Loading chart...
Key Metrics
P/E27.31
EPS13.80
Book Value18.51
Price to Book20.36
Debt/Equity490.28
% Insiders0.225%
Growth
Revenue Growth0.10%
Earnings Growth0.65%
Dividend
Dividend Yield2.29%
Annual dividends8.63 EUR
Ex-Div. DateAug. 21, 2026
Payout60.87%
5y avg Yield3.06%

DCF Valuation

Tweak assumptions to recompute fair value for Amgen Inc. (AMGN.VI)
Currency: EUR
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Amgen Inc. Logo Amgen Inc. Analysis (AMGN.VI)

United States Health Care Official Website Stock

Is Amgen Inc. a good investment? Amgen Inc. (AMGN.VI) is currently trading at 376.85 EUR.

In terms of valuation, the stock trades at a P/E ratio of 27.31. This valuation is generally in line with the broader market.

For income investors, Amgen Inc. pays a dividend yield of 2.29%. With a payout ratio of 61%, the dividend appears sustainable.

Investor FAQ

Does Amgen Inc. pay a dividend?

Yes, it pays an annual dividend of 8.63 EUR (2.29% yield).

What asset class is Amgen Inc.?

Amgen Inc. is classified as a Stock. You can compare it against 15 other assets in the "Related Symbols" list on this page.

Company Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Exchange Ticker
HEL (Finland) AM1.HE
BER (Germany) AMG.BE
DUS (Germany) AMG.DU
HAN (Germany) AMG.HA
NMS (United States) AMGN
GER (Germany) AMG.DE
MUN (Germany) AMG.MU
BUE (Argentina) AMGN.BA
FRA (Germany) AMG.F
HAM (Germany) AMG.HM
MEX (Mexico) AMGN.MX
VIE (Austria) AMGN.VI
IOB (United Kingdom) 0R0T.IL
SAO (Brazil) AMGN34.SA
STU (Germany) AMG.SG
Trades
Dividend Yield
2.29%
5y avg 3.06%
Annual Dividends
8.63EUR
Next Ex. Div Date
Aug. 21, 2026
Payout Ratio
60.87%
Dividend History paid per year (EUR)
Historical Dividends
Year Total Dividends
2027
7.07 EUR
Aug. 20, 2027 (estimated) 2.3563
May 21, 2027 (estimated) 2.3563
Feb. 19, 2027 (estimated) 2.3563
2026
8.72 EUR
Nov. 20, 2026 (estimated) 2.2254
Aug. 21, 2026 2.1634
May 15, 2026 2.1634
Feb. 13, 2026 2.1634
2025
8.17 EUR
Nov. 21, 2025 2.0432
Aug. 22, 2025 2.0432
May 16, 2025 2.0432
Feb. 14, 2025 2.0432
2024
7.73 EUR
Nov. 18, 2024 1.9316
Aug. 16, 2024 1.9316
May 16, 2024 1.9316
Feb. 15, 2024 1.9316
2023
7.31 EUR
Nov. 16, 2023 1.8286
Aug. 17, 2023 1.8286
May 17, 2023 1.8286
Feb. 14, 2023 1.8286
2022
6.66 EUR
Nov. 16, 2022 1.6655
Aug. 17, 2022 1.6655
May 16, 2022 1.6655
Feb. 14, 2022 1.6655
2021
6.04 EUR
Nov. 15, 2021 1.5110
Aug. 16, 2021 1.5110
May 14, 2021 1.5110
Feb. 11, 2021 1.5110
2020
5.49 EUR
Nov. 13, 2020 1.3736
Aug. 14, 2020 1.3736
May 15, 2020 1.3736
Feb. 13, 2020 1.3736
2019
4.98 EUR
Nov. 14, 2019 1.2448
Aug. 14, 2019 1.2448
May 16, 2019 1.2448
Feb. 14, 2019 1.2448
2018
4.53 EUR
Nov. 15, 2018 1.1332
Aug. 16, 2018 1.1332
May 16, 2018 1.1332
Feb. 14, 2018 1.1332
2017
1.97 EUR
Nov. 16, 2017 0.9873
Aug. 16, 2017 0.9873
Upcoming Dividends
Name Payment Date Status Amount
Amgen Inc. Aug 21, 2026 2.16342 EUR
Amgen Inc. May 15, 2026 2.16342 EUR
Amgen Inc. Feb 13, 2026 2.16342 EUR
Amgen Inc. Nov 21, 2025 2.04323 EUR
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion